Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study.

Robert W MarshMark S TalamontiMarshall S BakerMitchell PosnerKevin RogginJeffrey MatthewsDaniel CatenacciMark KozloffBlase PoliteMichele BrittoChi WangHedy Kindler

Published in: Journal of surgical oncology (2017)

PST using mFOLFIRINOX in resectable PDAC is feasible and tolerable. R0 resection rate is high and survival promising, requiring longer follow-up and larger studies for definitive assessment.

Keyphrases

locally advanced
rectal cancer
liver metastases
squamous cell carcinoma
radiation therapy
case control
bone marrow